Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [ <scp> <sup>11</sup> C </scp> ]Telmisartan-Reference-Cited by-同舟云学术

Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [ ¹¹ C ]Telmisartan

Published:2022-09-30 Issue:6 Volume:112 Page:1264-1270
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

van der Hoek Sjoukje¹^ORCID,Mulder Douwe J.²^ORCID,Willemsen Antoon T.M.³,Visser Ton⁴,Heeres Andre⁴⁵,Slart Riemer H.J.A.³,Elsinga Philip H.³,Heerspink Hiddo J.L.¹,Stevens Jasper¹^ORCID

Affiliation:

1. Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen, University of Groningen Groningen The Netherlands

2. Division of Vascular Medicine, Department of Internal Medicine University Medical Center Groningen, University of Groningen Groningen The Netherlands

3. Department of Nuclear Medicine and Molecular Imaging University Medical Center Groningen, University of Groningen Groningen The Netherlands

4. Symeres Groningen The Netherlands

5. Hanze University of Applied Sciences Groningen The Netherlands

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2744

Reference18 articles.

1. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

2. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

3. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

4. The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers